Healthcare
H.U. Group Holdings, Inc.(MRCHF)
Live Price
Offline$20.05
+0.00% today
Window Change
+1.52%
Window
May 4, 2026 → Jun 23, 2026
- Market Cap
- $175.48B
- Revenue Growth
- +2.6%
- EPS Growth
- +136.6%
- Dividend Yield
- 4.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 30 bars · May 4, 2026 → Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
H.U. Group Holdings, Inc. (MRCHF) is a Healthcare stock with a market cap of $175.48B and listed on OTC. The stock last traded around $20.05 and up 1.5% across the available one-year price window (May 4, 2026 → Jun 23, 2026). Baseline metrics include revenue growth of +2.6%, EPS growth of +136.6%, a dividend yield of 4.0%. What stands out right now is revenue +2.6%, EPS +136.6%, free cash flow +1258.1% with operating margin 1.7% and ROIC 1.4%. The dividend matters to the case here, with a current yield around 4.0%. Valuation already assumes a fairly strong business story at P/E 30.9 and price/sales 0.7. Stock Foundry combines MRCHF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+2.6% vs +7.6% peer median
Operating Margin
Below sector median
+1.7% vs +19.4% peer median
P/E
Below sector median
30.9 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +2.6% and EPS at +136.6%, with operating margin around 1.7%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 4.0%, which matters if the thesis depends on income as much as growth.
Benchmark Edge
MRCHF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MRCHF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MRCHF Max Drawdown
-6.07%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MRCHF and SPY.
Company Overview
H.U. Group Holdings, Inc.
Other OTC
H.U. Group Holdings, Inc., through its subsidiaries, provides laboratory testing products and services in Japan. The company offers lab testing and its related services to medical institutions; self-medication services; food, environment, and cosmetic testing services; and testing services through corporate health insurance associations. It also researches, develops, manufactures, and sells in vitro diagnostic devices, which includes the LUMIPULSE, an automatic chemiluminescent enzyme immunoassay system that offers reagents for infectious disease, cancer, and lifestyle disease to medical institutions and testing centers; and ESPRINE, a rapid diagnostics kit series for influenza, hepatitis B, and the novel coronavirus, as well as supplies ingredients for test drugs. In addition, the company provides support services related to hospital administration work, including aid for surgical procedures and endoscope room work, inspection and maintenance services for medical equipment, and in-hospital logistics management and transportation services; and rents and sells nursing-care equipment and supplies. Further, it offers home-visit nursing care services. The company was formerly known as Miraca Holdings Inc. and changed its name to H.U. Group Holdings, Inc. in July 2020. H.U. Group Holdings, Inc. was incorporated in 1950 and is headquartered in Tokyo, Japan.
- Leadership
- Goki Ishikawa
- IPO Date
- Aug 3, 2012
- Employees
- 5.3k
- Street Address
- Shinjuku Mitsui Building
- Mailing
- Tokyo, 163-0408
- Region
- Tokyo, JP
- Reporting Currency
- USD
- Investor Line
- 81 3 5909 3335
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 30.9
- EV/EBITDA
- 6.7
- Price/Sales
- 0.7
- Price/Book
- 1.3
Growth
- Revenue
- +2.6%
- EPS
- +136.6%
- Free Cash Flow
- +1258.1%
Profitability
- Gross Margin
- 28.7%
- Operating Margin
- 1.7%
- Net Margin
- 2.2%
- ROE
- 4.1%
- ROIC
- 1.4%
Balance Sheet
- Debt/Equity
- 0.52
- Current Ratio
- 1.80
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.